Applied DNA Sciences, Inc. (APDN)

NASDAQ: APDN · IEX Real-Time Price · USD
1.948
+0.073 (3.89%)
At close: May 22, 2024, 3:59 PM
1.850
-0.098 (-5.03%)
After-hours: May 22, 2024, 7:26 PM EDT
3.89%
Market Cap 1.92M
Revenue (ttm) 5.52M
Net Income (ttm) -12.50M
Shares Out 984.73K
EPS (ttm) -17.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 88,344
Open 2.000
Previous Close 1.875
Day's Range 1.850 - 2.050
52-Week Range 1.830 - 37.200
Beta 0.25
Analysts Strong Buy
Price Target 7.00 (+259.34%)
Earnings Date May 10, 2024

About APDN

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-base... [Read more]

Sector Healthcare
Founded 1983
Employees 52
Stock Exchange NASDAQ
Ticker Symbol APDN
Full Company Profile

Financial Performance

In 2023, APDN's revenue was $13.37 million, a decrease of -26.43% compared to the previous year's $18.17 million. Losses were -$9.95 million, 18.7% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for APDN stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(259.34% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML

STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚHK...

9 days ago - Accesswire

Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial ...

12 days ago - Accesswire

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notific...

12 days ago - Accesswire

Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program

Award Seeks to Demonstrate Feasibility of Manufacturing mRNA Vaccines in Only 7 Days  STONY BROOK, NY / ACCESSWIRE / April 25, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader i...

27 days ago - Accesswire

Applied DNA Announces 1-For-20 Reverse Stock Split

STONY BROOK, NY / ACCESSWIRE / April 22, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-f...

4 weeks ago - Accesswire

Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start

- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods - - Project Slated for Completion Coincident with Company's Planned Initiation of GMP Manufacturing for Linea ™ DNA IVT...

2 months ago - Accesswire

Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress

STONY BROOK, NY / ACCESSWIRE / March 14, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will showcase its Linea™ IVT and Linea™ DNA platforms at...

2 months ago - Accesswire

Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results

- Company On Track to Initiate First-Phase GMP Production Capacity for mRNA Critical Starting Materials During First Half of Calendar 2024, Projects Initial Facility Capacity to Enable up to $15 Milli...

3 months ago - Accesswire

Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024

STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today annou...

3 months ago - Accesswire

Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

STONY BROOK, NY / ACCESSWIRE / February 2, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has closed its previously anno...

3 months ago - Accesswire

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

STONY BROOK, NY / ACCESSWIRE / January 31, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that it has entered into securities pu...

4 months ago - Accesswire

Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology's mRNA Manufacturing Workflow

- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times - STONY BROOK, NY and NEED...

5 months ago - Accesswire

Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results

- Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / December 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in P...

5 months ago - Accesswire

Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023

STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today annou...

6 months ago - Accesswire

Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

STONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the receipt of a f...

6 months ago - Accesswire

Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)

- Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA - - Extension Enabled by the Company's Ongoing Platform Development and Optimization - STONY B...

6 months ago - Accesswire

Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform

- Preclinical Orders for Additional Customers Underway - STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-ba...

6 months ago - Accesswire

Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals

Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNA™ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the Dependence on Extreme Cold Chains of Today's mRNA Vaccines ST...

8 months ago - Accesswire

Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA Production Previously Led Manufacturing Operations Scale-up for the BioNTech/Pfi...

9 months ago - Accesswire

Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

STONY BROOK, NY / ACCESSWIRE / August 29, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the general availabi...

9 months ago - Accesswire

Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

STONY BROOK, NY / ACCESSWIRE / August 23, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the filing with the ...

9 months ago - Accesswire

Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update

Conference Call/Webcast Scheduled for Today at 4:30 PM ET STONY BROOK, NY / ACCESSWIRE / August 10, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-ba...

10 months ago - Accesswire

Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023

STONY BROOK, NY / ACCESSWIRE / August 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announc...

10 months ago - Accesswire

Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences

STONY BROOK, NY / ACCESSWIRE / July 18, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced the participation of LineaRx, Inc., its...

11 months ago - Accesswire

Applied DNA Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT(TM) Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach

- Platform Enables Customers to Manufacture mRNA with Substantial Reduction in dsRNA and Manufacturing Complexities; Integrable into Current mRNA Workflows - - Platform Currently Available Under Early...

11 months ago - Accesswire